Related Experiment Video
Updated: Aug 15, 2026
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
New look at myocardial infarction: toward a better aspirin
R J Bing1, T Yamamoto, M Yamamoto
1Department of Experimental Cardiology, Huntington Medical Research Institutes, Pasadena, CA, USA.
Insights
New aspirin formulations aim to reduce side effects by targeting inflammation and delivering nitric oxide (NO). While promising for early myocardial infarction, they do not prevent aspirin
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Inflammation Research
Background:
- Infarcted heart muscle produces nitric oxide (NO), prostacyclin, and thromboxane.
- Cardiac macrophages play a key role in the inflammatory response post-myocardial infarction.
- Aspirin, while effective, has gastrointestinal and renal side effects, and a risk of hemorrhagic stroke.
Purpose of the Study:
- To review the evidence for NO and related compound formation in myocardial infarction.
- To explore novel aspirin modifications designed to mitigate side effects and improve therapeutic outcomes.
- To assess the potential benefits and limitations of these new aspirin formulations.
Main Methods:
- Review of existing scientific literature on NO, prostacyclin, thromboxane, and aspirin in myocardial infarction.
- Analysis of strategies for modifying aspirin, including selective COX-2 inhibition and NO-delivery.
- Evaluation of studies on NO-aspirin and combined NO-donor with aspirin therapies.
Main Results:
- Evidence supports the role of NO and inflammatory cells in myocardial infarction.
- Novel aspirin modifications include selective COX-2 inhibitors, NO-aspirins, and NO-donor combinations.
- NO-aspirins and NO-donor combinations show promise for early myocardial infarction treatment.
- Aspirin's antithrombotic effect, crucial for preventing clots, remains linked to hemorrhagic stroke risk, a complication not addressed by new formulations.
Conclusions:
- Modified aspirin formulations offer potential advantages in managing myocardial infarction by reducing side effects.
- NO-aspirins and NO-donor combinations may be beneficial in the acute phase of myocardial infarction.
- The inherent risk of hemorrhagic stroke associated with aspirin's antithrombotic action persists with current novel aspirin developments.
Abstract:
The evidence for the formation of NO and of its oxidation products, as well as of prostacyclin and thromboxane by the infarcted heart muscle is reviewed. The importance of inflammatory cells, primarily macrophages of cardiac origin is documented. Because of its side effects on gastric mucosa and kidney by aspirin, several modifications of aspirin are currently being developed. These are based on eliminating their inflammatory effect by selective inhibition of COX-2, or by attaching an NO-delivering side chain to the aspirin molecule (NO-aspirin), or by combining two preparations, an NO donor with aspirin. NO-aspirins and the combination of an NO-donor with aspirin promise to be beneficial in the early stages of myocardial infarction. Unfortunately, the main beneficial effect of aspirin, that of inhibition of thrombus formation, is also the cause for its most dreaded complication, hemorrhagic stroke. None of the new aspirins is able to prevent this complication.
Related Concept Videos
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies